Patient response and efficacy outcomes. (A) Best change in target lesion size by histological subtype. (B) Duration of response. (C) Response in patients achieving a CR or PR. (D) PFS. (E) Overall survival. Median DoR includes censored values for 13 patients, and median PFS includes censored values for 17 patients. The percentage best change in the sum of the diameters of all target lesions from baseline as assessed by the investigator is shown; the best change in target lesion size per the investigator onsite assessment could not be determined in 4 patients. DoR, duration of response; NE, not evaluable; OS, overall survival. *Each bar represents 1 patient.